Advertisement
Advertisement
PASG
Passage Bio, Inc. Common Stock
3.98
USDSponsored
+0.52
+14.88%
Nov 06, 15:59 UTC -5
Closed
After-Market
3.83
-0.15
-3.70%
Passage Bio, Inc. Common Stock (PASG) Earnings
PASG Earnings Reports
Positive Surprise Ratio
PASG beat 15 of 26 last estimates.
58%
Next Report
Next Week
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$2.48
Implied change from Q2 26 (Revenue/ EPS)
--
/+1.64%
Implied change from Q3 25 (Revenue/ EPS)
--
/+1.64%
Passage Bio, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, PASG reported earnings of -2.44 USD per share (EPS) for Q2 26, beating the estimate of -2.69 USD, resulting in a 9.62% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -2.48 USD, with revenue projected to reach -- USD, implying an increase of 1.64% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Passage Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Passage Bio, Inc. Common Stock reported EPS of -$2.44, beating estimates by 9.62%, and revenue of $0.00, 0% as expectations.
How did the market react to Passage Bio, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -1.82%, changed from $4.40 before the earnings release to $4.32 the day after.
When is Passage Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Passage Bio, Inc. Common Stock's next earnings report?
Based on 4
analysts, Passage Bio, Inc. Common Stock is expected to report EPS of -$2.48 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.